- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Once-daily relugolix combination therapy improves uterine fibroid-associated heavy menstrual bleeding
Uterine fibroids, noncancerous pelvic tumors in premenopausal women, depend on estrogen and progesterone. Age, race, genetic predisposition, and lifestyle are risk factors associated with this condition. Black women have an 89% lifetime UF prevalence, 3-4 times higher than that of other races.
According to a recent study published in the American Journal of Obstetrics and Gynecology, Relugolix combination therapy reduces heavy menstrual bleeding for 82.9% of Black women with uterine fibroids, along with reducing the severity of symptoms and distress.
In the LIBERTY Long-Term Extension study, the once-daily relugolix combination therapy improved heavy menstrual bleeding associated with uterine fibroids in the 52-week treatment period. The study specifically aimed to evaluate the efficacy and safety of the therapy in Black or African American women with uterine fibroids, who often experience a greater disease burden compared to other racial groups and are traditionally underrepresented in clinical trials.
Black/African American premenopausal women with UF and heavy menstrual bleeding who completed 24-week LIBERTY 1 or LIBERTY 2 trials were eligible for the 28-week LIBERTY Long-Term Extension study. The primary goal was achieving a menstrual blood loss volume of less than 80 mL and a reduction of at least 50% menstrual blood loss volume from the baseline to the last 35 days of treatment. Secondary outcomes included rates of amenorrhea and changes in symptom burden and quality of life.
Key findings from the study are:
- 241/477 women enrolled in the study self-identified as Black or African American.
- Among women receiving continuous relugolix combination therapy for 52 weeks, 58/70 women met the treatment responder criteria.
- A reduction in menstrual blood loss volume from baseline to week 52 was demonstrated.
- 64.3% of women achieved amenorrhea; 59.1% of women with anaemia at the pivotal study baseline achieved a substantial improvement (>2 g/dL) in haemoglobin levels, decreased symptom severity and distress, and improved life quality.
- The most frequently reported adverse events were hot flush (12.9%), headache (5.7%), and hypertension (5.7%).
- Bone mineral density was preserved through 52 weeks.
Once-daily relugolix combination therapy improved uterine fibroid-associated heavy menstrual bleeding.
Dr Elizabeth A. Stewart, a professor of obstetrics and gynaecology at Mayo Clinic, said that Black/African American women with fibroids often experience more severe symptoms and a lower quality of life, but relugolix combination therapy is a safe and effective treatment option for them.
Reference:
Stewart, E et al. Relugolix combination therapy in Black/African American women with symptomatic uterine fibroids: LIBERTY Long-Term Extension study. American Journal of Obstetrics and Gynecology. https://doi.org/10.1016/j.ajog.2023.10.030
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751